Diabetes Research and Clinical Practice - Volume 120 - Supplement 1 - October 2016

116 / 244

enhances GLP-1 secretion, whereas acarbose improves post-
prandial dyslipidemia in patients with T2DM.
PD-21
Influence on urination of SGLT2 inhibitor in type 2 diabetes
Junko SASAKI 1*, Junpei SHIKUMA1, Rokuro ITO1,
Masato ODAWARA1. 1The Department of Diabetes, Endocrinoligy
and Metabolism, Tokyo Medical University Hospital, Japan
Background: Sodium glucose co-transporter 2 (SGLT2) inhibi-
tors are new antidiabetic drugs that increase urinary excretion
of glucose. They have polyuria and pollakiuria as adverse
events because of their diuretic effect. Therefore we investi-
gated influence on urinary disorder of ipragliflozin (Ipra) and
tofogliflozin (Tofo).
Method: A prospective randomized study was conducted on 35
patients with type 2 diabetes [male: n = 22, female: n = 13, age:
55 ± 9, BMI: 27.9 ± 3.6, HbA1c: 7.7 ± 1.0%]. Twenty one patients
received Ipra and 14 patients receiverd Tofo daily for 1 month.
International Prostate Symptom Score (IPSS), overactive
Bladder Symptom Score (OABSS), International Consultation
on Incontinence Question- Short Form (ICIQ-SF) were eval-
uated at before the treatment and after 1 month.
Results: After 1 month of the treatment, body weight (75.3 ±
13.2 →74.2 ± 13.2 kg, p < 0.001), BMI (28.0 ± 3.6 →27.5 ± 4.0, p <
0.001), HbA1c (7.7 ± 1.0 →7.5 ± 0.8%, p < 0.001) and γ-GTP (42.6 ±
32 →36.5 ± 24.0, p < 0.001) improved significantly. In each total
score of IPSS, OABSS and ICIQ-SF, there was no significant
change. In each question of scores, there were significant
increases in “How often do you usually urinate during the
day? ” (0.4 ± 0.6→0.7 ± 0.5, p = 0.008) of OABSS, “How often do
you leak urine? ” (0.5 ± 0.9→0.8 ± 1.3, p = 0.031) and “Overall,
how much does leaking urine interfere with your everyday
life?” (0.3 ± 0.9→0.8 ± 1.5, p = 0.016) of ICIQ-SF. In patients taking
Ipra, there was no significant change in all scores. But in
patients taking Tofo, there were significant changes in total
scores of IPSS and ICIQ-SF. In the male patients with IPSS more
than eight points which moderate benign prostatic hyperpla-
sia is doubted (n = 3), there was no meaningful change in each
score. In the patients with OABSS score more than 3 points
which overactive bladder was doubted (n = 11), there was no
meaningful change neither.
Conclusion: In type 2 diabetes, it was shown that SGLT2
inhibitors can make their glucose control better and make
their body weight decrease without any urinary disorder.
Some studies were shown that Ipra makes nocturia worse.
However in our study, there was no significant change. We
may suggest that SGLT2 inhibitors were useful for diabetes
patients with and without any urinary disorder.
There are going to be more cases to present by the day of
meeting.
PD-22
Assess the efficacy differences of using long-acting insulin and
oral hypoglycemic agents in type 2 diabetes patients
Chiu-Ju CHEN 1*, Hui-Chen SU1. 1Department of Pharmacy, Chi-
Mei Hospital, Taiwan
Background: Type 2 diabetes patients usually use two to three
kinds of oral hypoglycemic agents, but the treatment effects
are poor. According to the latest clinical studies that long-
acting insulin and oral hypoglycemic agents can control blood
sugar, decrease the risk of blood vessels, and improve quality
of life in diabetes.
Objectives: This study evaluated the efficacy of five kinds of
oral hypoglycemic agents with long-acting insulin.
Methods: Using retrospective mode to analyze a medical
center of outpatient cases in 2014, the subjects are 65 years
old with type 2 diabetes, the serumof HbA1C level greater than
7 or more, using insulin glargine and oral hypoglycemic drug to
treatment. According to the oral hypoglycemic agents, we
divided into five groups: glibenclamide (5 mg), glimepiride
(2 mg), pioglitazone (15 mg), sitagliptin (100 mg), saxagliptin
(5 mg). We used SPSS statistical software for ANOVA analysis
and assessed the correlation of HbA1C level and the five
groups before and after treatment.
Results: In this study, the patients have received 174 cases. We
found the mean deviation of HbA1C level for the five groups
before and after treatment, it had statistical significant
disparity (p < 0.05). The HbA1C level is reduced 0.32% using
insulin glargine and glibenclamide, and the HbA1C level is
reduced 0.15% using insulin glargine and glimepiride, and the
HbA1C level is reduced 0.49% using insulin glargine and
pioglitazone, and the HbA1C level is reduced 0.51% using
insulin glargine and sitagliptin, and the HbA1C level is reduced
0.79% using insulin glargine and saxagliptin.
Conclusions: We recommended the best treatment that using
insulin glargine with saxagliptin (DPP-4 enzyme inhibitor) in
the type 2 diabetes patients.
PD-23
The use and the appropriateness of antidiabetic agents in
primary referral hospital
Nikko DARNINDRO1*, Ahmad Fariz Malvi Zamzam ZEIN2.
1Department of Internal Medicine, Cilincing General Hospital,
2Departement of Health, Central Board of Nahdlatul Ulama,
Indonesia
Background: Diabetes mellitus (DM) is growing worldwide,
especially in developing countries. The management of
diabetes includes lifestyle modification, medical nutrition
therapy, and life-long medication, in accordance with
patient-centered approach. The caution and contraindication
are highly warranted in considering the proper long term use
of antidiabetic drugs. This study was aimed to identify profile
and the appropriateness of antidiabetic agents in primary
referral hospital.
Methods: A cross-sectional study was conducted at Cilincing
General Hospital between December 2015 and February 2016.
The subjects were the patients who were referred from
primary health cares with clinically suspected for DM during
the study. Diabetes mellitus was diagnosed according to
Indonesian Society of Endocrinology guideline. The medica-
tion was listed based on the regiment given. The appropriate-
ness was assessed by matching the antidiabetic drug and the
contraindications.
Result: A total of 62 subjects were participated in the study
(75.80% were females). The mean age was 59.58 ± 8.77 years
old. Mean admission fasting blood sugar was 231.66 mg/dL (SD
94.01), mean body mass index was 25.23 ± 4.81 kg/m2, and
mean serum creatine was 1.27 ± 0.73. The use of oral antidia-
betic agents was metformin (96.80%), sulphonylureas (64.50%),
and insulin (19.40%), respectively. The regiments were given as
metformin monotherapy (14.5%), sulfonylurea monotherapy
(4.8%), combination of metformin and sulfonylurea (61.3%),
and combination of metformin and insulin (19.4%). Of subjects
who received metformin, there were 4 subjects (6.67%) with
eGFR (CKD-EPI) <30 mL/min/1.73 m2, because rejecting insulin
therapy. There were 19 subjects (48.7%) receiving sulfonylurea
with eGFR (CKD-EPI) <60 mL/min/1.73 m2. No history of
hypoglycemia was reported by the subjects.
Conclusion: Metformin is the most frequently prescribed drug.
The use of metformin and sulfonylurea in renal dysfunction is
high. The awareness and monitoring of antidiabetic drugs
related their caution and contraindication are urgently
needed.
Abbreviations: DM: Diabetes Mellitus / eGFR: estimated
Glomerular Filtratrion Rate / CKD-EPI: Chronic Kidney Disease
Epidemiology Collaboration
Poster Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S65–S211 S98